59215.1 IP-LS

Résumé

Nanomedicine-based targeted therapy of atherosclerosis

Textes supplémentaires

Abstract

Atherosclerosis is the main cause of death but drug therapy is limited. This pilot project will show the potential of a targeted, personalized nanodrug & companion diagnostics with profound effect for atherosclerosis reversal such that a full industrial translation of a product can be started.

Participants

Marc Wolf

Kontaktperson

Universitätsspital Basel CLINAM Marc Wolf Bernoullistrasse 20 4056 Basel BS CH

Détails du projet

Office de recherche: INNOSUISSE
Statut du projet: Abgeschlossen
Type de projet: Forschungsprojekt
Date de début: 2022-05-31
Date de fin: 2023-11-30
Coûts totaux approuvés: CHF 551940.39
Section: 60 Life Sciences
Domaine politique NABS: Industrielle Produktivität und Technologie

Disciplines de recherche

T410 Pharmaceuticals and related technologies 100.0%